Daily Morning Note – 19 November 2021

PHILLIP SUMMARY

Asian stocks looked set for a mixed start Friday as Chinese technology shares struggle, contrasting with a rally in their U.S. counterparts that propelled Wall Street equities to a record high.

Australian shares and futures for Japan were steady, while Hong Kong contracts slid. A tumble in the likes of e-commerce firm Alibaba Group Holding Ltd. and video-streaming platform operator Bilibili Inc. hurt an index of U.S.-listed Chinese stocks. Alibaba slashed its outlook for fiscal 2022 revenue amid intensifying competition, dwindling consumer spending and regulatory curbs.

In the U.S., a clutch of megacap tech companies rose, helping to take the Nasdaq 100 and S&P 500 to new peaks in a choppy session ahead of Friday’s options expiration. U.S. futures climbed in early Asian trading.


BREAKING NEWS

SG

Myanmar’s Yoma Siloam Hospital Pun Hlaing (PHH) has become the first private hospital group to procure Sinopharm’s Covid-19 vaccine, OUE Lippo Healthcare (OUELH) said in an exchange filing on Thursday (Nov 18). The hospital group, a joint venture between OUELH and First Myanmar Investment, received its first shipment of the vaccine that day, said the Catalist-listed company. This comes after PHH received approval from Myanmar’s Ministry of Health and the Food and Drug Administration to import up to 400,000 doses of the Sinopharm vaccine, which is on the World Health Organization’s Emergency Use Listing.

Transport operator ComfortDelGro Corporation, through its wholly-owned private bus company ComfortDelGro Bus, is set to to operate Singapore’s largest electrified private bus fleet after winning a S$30 million contract to operate the shuttle bus service at the National University of Singapore (NUS) campus. In a press statement on Thursday (Nov 18), the transport operator said the multi-year contract is for the electrification of the university’s entire fleet of shuttle service buses. The NUS electric buses, which will begin operations from third quarter of 2022, will continue to serve the 8 existing shuttle bus routes within the campus covering NUS Kent Ridge campus, University Town as well as NUS Bukit Timah campus daily from 7 am to 11 pm, including public holidays.

Tourism attractions operator Straco Corporation posted a net profit of S$4.36 million in the third quarter ended Sep 30, the mainboard-listed company said in a business update on Thursday. This represents a 32.4 per cent decline from the same period a year ago, when the group reported a net profit of S$6.45 million. The group attributed Q3’s net profit to foreign exchange gain, with the Renminbi strengthening against the Singapore dollar, as well as receipts from the Singapore government’s Job Support Scheme and land rental waiver for the quarter.

Engineering solutions firm Ellipsiz on Thursday (Nov 18) announced it is planning a foray into the agri-food industry. In a bourse filing, Ellipsiz says it has entered into a conditional sale and purchase agreement to buy a 20 per cent stake in ISE Capital Management (ICM) for S$2 million. ICM owns a 70 per cent interest in ISE Foods Holdings (IFH), which had signed a memorandum of understanding with the Singapore Food Agency in September for IFH to develop and operate the fourth egg farm in Singapore.

US

Alibaba on Thursday missed revenue and earnings expectations for the September quarter, as slowing economic growth in China weighed on results, adding to regulatory headwinds. The company also slashed its revenue guidance for its current fiscal year. It previously expected to bring in 930 billion yuan, which would have been about 29.5% year-on-year growth. But it now expects growth to be between 20% and 23% year-on-year.

AstraZeneca’s antibody treatment has been shown to be highly effective at preventing Covid-19 in people who may not respond well to vaccines, according to new clinical trial results. The data showed that patients given a single injection of the antibody treatment, known as AZD7442, were 83% less likely to develop symptomatic cases of the coronavirus than participants who were given a placebo. An earlier analysis of the trial, conducted three months after the treatment was administered, had shown that the risk of developing severe disease was reduced by 77%.

Starbucks is opening a pick-up cafe in midtown Manhattan with Amazon that uses the retail giant’s cashierless technology to attract busy consumers who want to buy coffee or snack quickly. The partnership with Amazon is the latest step in Starbucks’ plan to adapt its locations to consumers’ new habits. Nearly a year and a half ago, Starbucks announced it was accelerating plans to revamp its U.S. footprint, inspired by the pandemic’s abrupt shifts to how consumers wanted to buy and drink their coffee. In addition to shuttering as many as 400 stores in 18 months, the strategy included opening more pick-up locations in dense urban markets and installing walk-up windows and double drive-thru lanes in suburban areas.

Ford Motor plans to increase its production capacity of electric vehicles to 600,000 units globally by 2023, which CEO Jim Farley expects would make the company the second-largest U.S.-based producer of EVs, behind Tesla. Farley said the increase would double the number of EVs the company had initially expected to produce over the next 24 months, according to a report Thursday from Automotive News. That production is expected to be spread across Ford’s first three new EVs: the Mustang Mach-E, F-150 Lightning and E-Transit. It would come before production is expected to begin at a newly announced EV assembly plant in Tennessee, according to the Detroit-based publication.

Baidu plans to launch its driverless taxi service in 100 cities by 2030, as the Chinese search giant looks to diversify its business beyond advertising. Currently, Baidu operates its Apollo Go robotaxi service in five Chinese cities. Users can hail an autonomous car via an app. The company wants to expand Apollo Go to 65 cities by 2025 and then 100 cities by 2030, Baidu CEO Robin Li said in an internal letter that was made public.


Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, CNBC, PSR

POEMS Podcast: Let the Money Talk

Recent Podcasts:

Daily Morning Note – November 18, 2021

Keppel Corp – SGX Company Insights Ep 42

Daily Morning Note – November 17, 2021

Visit www.stocksbnb.com to learn more!


Join our Phillip Securities Research Telegram channel for the latest update on our stock coverage!

Click here to join: https://t.me/stocksbnb


Webinar Of The Week

Weekly Market Outlook: Lendlease, Sunpower Group, Comfort DelGro, PropNex, Starhub, SPH, SG Weekly..

Date: 15 November 2021

For more on Market Outlook

Updates summarised in 3 minutes

Phillip Research in 3 minutes: #29 Keppel Corporation; Initiation

For more videos on Phillip in 3 Mins


Read the research report(s), available through the link(s) above, for complete information including important disclosures Important Information





Disclaimer
The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.
Confidentiality Note
This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.

 

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com